Current theories maintained that trastuzumab resistance mainly resulted from HER2 mutation (Xu et al., 2017), antigenic epitope variation (Arribas et al., 2011), compensatory pathway activation (Baselga et al., 2014) and tumor heterogeneity (Marchiò et al., 2021). The gene discussed is ERBB2; the disease is neoplasm.